Table 1.
Patient characteristics at baseline (T0)
| Characteristics | Group 1 (n = 37) | Group 2 (n = 37) | p value |
|---|---|---|---|
| Age (years) | 68.3 ± 13.7 | 66.1 ± 12.1 | 0.2 |
| Sex (F/M), n | 24/13 | 20/17 | 0.5 |
| BMI, kg/m2 | 26.3 | 26.8 | 0.8 |
| Duration of pain, weeks | 12.7 ± 4.2 | 11.1 ± 3.5 | 0.1 |
| VAS score (0–100), mm | 62.4 ± 13.6 | 68.7 ± 17.3 | 0.2 |
| WOMAC score (pain) | 6.6 ± 2.0 | 7.2 ± 2.4 | 0.1 |
| WOMAC score (disability) | 20.6 ± 3.8 | 22.1 ± 4.3 | 0.3 |
| WOMAC score (stiffness) | 3.0 ± 1.5 | 2.9 ± 1.9 | 0.9 |
| WORMS | 6.9 ± 2.6 | 7.6 ± 3.7 | 0.2 |
Data are presented as mean ± standard deviation or N (%) unless otherwise indicated. Group 1: intramuscular clodronate 200 mg daily for 15 days, then once weekly for the next 11.5 months; group 2: intramuscular clodronate 200 mg daily for 15 days, then once weekly for the next 2.5 months
BMI body mass index, F female, M male, VAS visual analog scale, WOMAC Western Ontario and McMaster University Osteoarthritis Index, WORMS whole organ magnetic resonance imaging score